Literature DB >> 9386177

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.

J Ménard1, D J Campbell, M Azizi, M F Gonzales.   

Abstract

BACKGROUND: Blockade of type 1 angiotensin (Ang) II receptors combined with ACE inhibition may amplify the efficacy of the renin-angiotensin system blockade because ACE inhibitors do not completely and permanently suppress Ang II production. METHODS AND
RESULTS: Enalapril or losartan (1, 3, 10, and 30 mg/kg) or their combination was administered for 2 to 4 weeks to spontaneously hypertensive rats. The combination of low doses of each agent induced greater reductions in blood pressure (BP) and left ventricular weight/body weight (LVW/ BW) ratio than monotherapy with the same or higher doses. When approximately equipotent regimens of enalapril, losartan, and their combination, as judged by BP fall, were compared, there were similar increases in plasma and renal renin and in plasma Ang-(1-7) and Ang I and similar reductions in plasma angiotensinogen. Enalapril alone reduced plasma Ang II levels, and losartan alone increased Ang II levels. The combination of enalapril with losartan prevented or reduced the increase in Ang II levels observed with losartan alone.
CONCLUSIONS: These findings show that the synergistic interaction between the effects of low doses of enalapril and losartan on BP and LVW/BW ratio is due to more effective inhibition of the renin-angiotensin system by their combination than by either agent alone. When both drugs are given together, the ACE inhibitor-induced fall in plasma Ang II results in modulation of the Ang II antagonist-induced reactive rise in Ang II, thereby lowering the plasma Ang II concentration, which competes with the antagonist for the Ang II receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386177     DOI: 10.1161/01.cir.96.9.3072

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.

Authors:  R Weidenbach; R Schulz; P Gres; M Behrends; H Post; G Heusch
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

Review 3.  Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.

Authors:  Boutros El-Haddad; Scott Reule; Paul E Drawz
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

4.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

5.  Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

6.  Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2013-04-30       Impact factor: 28.314

Review 7.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

8.  Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.

Authors:  Jürg Nussberger; Jürgen Bohlender
Journal:  Nat Rev Cardiol       Date:  2013-03-12       Impact factor: 32.419

9.  Major role for ACE-independent intrarenal ANG II formation in type II diabetes.

Authors:  Sungmi Park; Benjamin J Bivona; Hiroyuki Kobori; Dale M Seth; Mark C Chappell; Eric Lazartigues; Lisa M Harrison-Bernard
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-21

10.  Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.

Authors:  Ming Li; Ke Liu; Jan Michalicek; James A Angus; John E Hunt; Louis J Dell'Italia; Michael P Feneley; Robert M Graham; Ahsan Husain
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.